Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enveric Biosciences Inc (NQ: ENVB ) 0.4471 +0.0066 (+1.50%) Streaming Delayed Price Updated: 3:52 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Enveric Biosciences Inc < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic October 15, 2024 Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 15, 2024 Via Benzinga Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 October 15, 2024 From Enveric Biosciences Via Business Wire Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies October 04, 2024 Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. Via Benzinga Why Is Enveric Biosciences (ENVB) Stock Up 18% Today? July 30, 2024 Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning. Via InvestorPlace Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop September 26, 2024 From Enveric Biosciences Via Business Wire Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research September 25, 2024 Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being... Via Benzinga Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit September 25, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 04, 2024 From Enveric Biosciences Via Business Wire Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions August 13, 2024 From Enveric Biosciences Via Business Wire ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024 August 12, 2024 ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results August 12, 2024 From Enveric Biosciences Via Business Wire Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 30, 2024 Via Benzinga Why Is Imunon (IMNN) Stock Up 259% Today? July 30, 2024 Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial. Via InvestorPlace Why Is Ekso Bionics (EKSO) Stock Down 15% Today? July 30, 2024 Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday July 30, 2024 Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning! Via InvestorPlace Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket July 30, 2024 Via Benzinga Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally July 25, 2024 Via Benzinga Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally July 25, 2024 From Enveric Biosciences Via Business Wire Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement July 15, 2024 From Enveric Biosciences Via Business Wire New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies July 11, 2024 Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. Via Benzinga Topics Intellectual Property Exposures Intellectual Property Enveric Biosciences Announces Patent Granted for Drug Candidate July 10, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate June 25, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences to Participate in BIO International Convention 2024 May 30, 2024 From Enveric Biosciences Via Business Wire ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024 May 20, 2024 ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace 'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand May 16, 2024 Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the... Via Benzinga Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results May 15, 2024 From Enveric Biosciences Via Business Wire Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate May 14, 2024 Via Benzinga Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders May 14, 2024 From Enveric Biosciences Via Business Wire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 08, 2024 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.